To hear about similar clinical trials, please enter your email below
Trial Title:
the Value of Immunohistochemical Expression of Moesin in Endometrial Hyperplasia and Endometrial Carcinoma
NCT ID:
NCT05619159
Condition:
Endometrial Cancer and Endometrial Hyperplasia
Conditions: Official terms:
Endometrial Neoplasms
Endometrial Hyperplasia
Hyperplasia
Study type:
Observational
Overall status:
Unknown status
Study design:
Time perspective:
Retrospective
Intervention:
Intervention type:
Device
Intervention name:
microscopic pathological evaluation
Description:
description of moesin expression between endometrial hyperplasia and endometrial
carcinoma
Arm group label:
endometrial carcinoma smples
Arm group label:
endometrial hyperplasia samples
Summary:
Endometrial carcinoma (EC) is the most prevalent invasive carcinoma of the female genital
tract in developed countries, while it ranks as the second most frequently occurring
neoplasm of women in developing countries, after carcinoma of the cervix uteri. The vast
majority of ECs occur in perimenopausal and postmenopausal women .
ECs are classified into two distinct phenotypes; type I which represents more than 80% of
all cases of ECs, it has a favorable prognosis. This type is linked to excess, unopposed
hyper-estrogenic condition and it is almost always preceded by endometrial hyperplasia.
On the contrary, type II endometrial carcinoma is less common than type I, representing
less than 10% of all cases of ECs. Type II endometrial carcinomas are high grade, poorly
differentiated and estrogen-independent tumors .
Criteria for eligibility:
Study pop:
females presented to gynecology department in sohag university hospital and sohag
oncology center
Sampling method:
Probability Sample
Criteria:
Inclusion Criteria:
- Hysterectomy specimens diagnosed as endometrial hyperplasia and endometrial
adenocarcinoma.
- All cases of endometrial biopsies obtained by curettage (D&C) diagnosed as
endometrial hyperplasia.
- Cases of cyclical endometrium obtained from endometrial curettage or hysterectomy
specimens done for pathological conditions other than hyperplastic or neoplastic
endometrial lesions.
- Complete clinical data.
Exclusion Criteria:
- Patients with a history of preoperative chemotherapy and /or radiotherapy.
- Biopsies with predominantly blood clots.
- Insufficient or tiny tissue biopsies.
Gender:
Female
Gender based:
Yes
Minimum age:
N/A
Maximum age:
N/A
Locations:
Facility:
Name:
Sohag University Hospital
Address:
City:
Sohag
Country:
Egypt
Contact:
Last name:
Magdy M Amin, professor
Start date:
November 2022
Completion date:
May 2023
Lead sponsor:
Agency:
Sohag University
Agency class:
Other
Source:
Sohag University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05619159
